Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 304

1.
2.

Immunomagnetic nanoscreening of circulating tumor cells with a motion controlled microfluidic system.

Huang YY, Hoshino K, Chen P, Wu CH, Lane N, Huebschman M, Liu H, Sokolov K, Uhr JW, Frenkel EP, Zhang JXJ.

Biomed Microdevices. 2013 Aug;15(4):673-681. doi: 10.1007/s10544-012-9718-8.

3.

Challenges in the enumeration and phenotyping of CTC.

Coumans FA, Ligthart ST, Uhr JW, Terstappen LW.

Clin Cancer Res. 2012 Oct 15;18(20):5711-8. doi: 10.1158/1078-0432.CCR-12-1585. Epub 2012 Sep 25.

4.

Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.

Uhr JW, Huebschman ML, Frenkel EP, Lane NL, Ashfaq R, Liu H, Rana DR, Cheng L, Lin AT, Hughes GA, Zhang XJ, Garner HR.

Transl Res. 2012 May;159(5):366-75. doi: 10.1016/j.trsl.2011.08.003. Epub 2011 Sep 3.

5.

Microchip-based immunomagnetic detection of circulating tumor cells.

Hoshino K, Huang YY, Lane N, Huebschman M, Uhr JW, Frenkel EP, Zhang X.

Lab Chip. 2011 Oct 21;11(20):3449-57. doi: 10.1039/c1lc20270g. Epub 2011 Aug 24.

6.

Controversies in clinical cancer dormancy.

Uhr JW, Pantel K.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12396-400. doi: 10.1073/pnas.1106613108. Epub 2011 Jul 11. Review.

7.

Handheld histology-equivalent sectioning laser-scanning confocal optical microscope for interventional imaging.

Kumar K, Avritscher R, Wang Y, Lane N, Madoff DC, Yu TK, Uhr JW, Zhang X.

Biomed Microdevices. 2010 Apr;12(2):223-33. doi: 10.1007/s10544-009-9377-6.

PMID:
20012209
8.

Cancer diagnostics: one-stop shop.

Uhr JW.

Nature. 2007 Dec 20;450(7173):1168-9. No abstract available.

PMID:
18097389
9.

Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.

Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E.

Adv Cancer Res. 2007;97:189-202. Review.

PMID:
17419946
10.

Circulating tumor cells in patients with breast cancer dormancy.

Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW.

Clin Cancer Res. 2004 Dec 15;10(24):8152-62.

11.

Mathematical models of cancer dormancy.

Page K, Uhr JW.

Leuk Lymphoma. 2005 Mar;46(3):313-27. Review.

PMID:
15621821
12.

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW.

Clin Cancer Res. 2004 Oct 15;10(20):6897-904.

14.

Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.

Hsueh RC, Hammill AM, Lee JA, Uhr JW, Scheuermann RH.

BMC Immunol. 2002 Dec 6;3:16. Epub 2002 Dec 6.

15.

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV, Terstappen LW.

Int J Oncol. 2002 Nov;21(5):1111-7.

PMID:
12370762
16.

Dormancy in a model of murine B cell lymphoma.

Uhr JW, Marches R.

Semin Cancer Biol. 2001 Aug;11(4):277-83. Review.

PMID:
11513563
17.

A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas.

Marches R, Vitetta ES, Uhr JW.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3434-9. Epub 2001 Feb 27.

19.

Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death.

Hammill AK, Uhr JW, Scheuermann RH.

Exp Cell Res. 1999 Aug 25;251(1):16-21.

PMID:
10438567
20.
21.

Antigen receptor signaling induces differential tyrosine kinase activation and population stability in B-cell lymphoma.

Hsueh RC, Hammill AK, Marches R, Uhr JW, Scheuermann RH.

Curr Top Microbiol Immunol. 1999;246:299-304; discussion 305. Review. No abstract available.

PMID:
10396069
22.

Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state.

Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, Street NE.

J Immunol. 1999 Mar 1;162(5):2842-9.

23.

Detection and characterization of carcinoma cells in the blood.

Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW.

Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4589-94.

24.
25.

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES.

Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7509-14.

26.

Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established.

Vitetta ES, Tucker TF, Racila E, Huang YW, Marches R, Lane N, Scheuermann RH, Street NE, Watanabe T, Uhr JW.

Blood. 1997 Jun 15;89(12):4425-36.

27.

Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.

Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, Figg WD, Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe ES, Sausville EA.

Ann Intern Med. 1997 Jun 1;126(11):882-5. No abstract available.

PMID:
9163289
28.

Cancer dormancy: opportunities for new therapeutic approaches.

Uhr JW, Scheuermann RH, Street NE, Vitetta ES.

Nat Med. 1997 May;3(5):505-9. Review. No abstract available.

PMID:
9142117
29.

Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins.

Baluna R, Sausville EA, Stone MJ, Stetler-Stevenson MA, Uhr JW, Vitetta ES.

Clin Cancer Res. 1996 Oct;2(10):1705-12.

30.

Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma.

Ghetie MA, Podar EM, Gordon BE, Pantazis P, Uhr JW, Vitetta ES.

Int J Cancer. 1996 Sep 27;68(1):93-6.

31.

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.

Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES.

Blood. 1996 Aug 15;88(4):1188-97.

32.

Tumor dormancy and cell signaling: anti-mu-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction.

Racila E, Hsueh R, Marches R, Tucker TF, Krammer PH, Scheuermann RH, Uhr JW.

Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2165-8.

33.

Role of antibody signaling in inducing tumor dormancy.

Uhr JW, Marches R, Racila E, Tucker TF, Hsueh R, Street NE, Vitetta ES, Scheuermann RH.

Adv Exp Med Biol. 1996;406:69-74. Review. No abstract available.

PMID:
8910672
34.
35.

Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells.

Marches R, Racila E, Tucker TF, Picker L, Mongini P, Hsueh R, Vitetta ES, Scheuermann RH, Uhr JW.

Ther Immunol. 1995 Jun;2(3):125-36.

PMID:
8885131
36.

Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.

Racila E, Scheuermann RH, Picker LJ, Yefenof E, Tucker T, Chang W, Marches R, Street NE, Vitetta ES, Uhr JW.

J Exp Med. 1995 Apr 1;181(4):1539-50.

37.

Lyn tyrosine kinase signals cell cycle arrest in mouse and human B-cell lymphoma.

Scheuermann RH, Racila E, Uhr JW.

Curr Top Microbiol Immunol. 1995;194:313-21. No abstract available.

PMID:
7895504
38.

Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy.

Vitetta ES, Uhr JW.

Cancer Res. 1994 Oct 15;54(20):5301-9. Review. No abstract available.

39.
40.

Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells.

Scheuermann RH, Racila E, Tucker T, Yefenof E, Street NE, Vitetta ES, Picker LJ, Uhr JW.

Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4048-52.

41.

Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest.

Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES.

Blood. 1994 Mar 1;83(5):1329-36.

42.

Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.

Ghetie V, Swindell E, Uhr JW, Vitetta ES.

J Immunol Methods. 1993 Nov 5;166(1):117-22.

PMID:
8228282
43.

Induction of B cell tumor dormancy by anti-idiotypic antibodies.

Yefenof E, Picker LJ, Scheuermann RH, Vitetta ES, Street NE, Tucker TF, Uhr JW.

Curr Opin Immunol. 1993 Oct;5(5):740-4. Review.

PMID:
8240736
44.

Role of CD25+ and CD25-T cells in acute HIV infection in vitro.

Ramilo O, Bell KD, Uhr JW, Vitetta ES.

J Immunol. 1993 Jun 1;150(11):5202-8.

PMID:
8496611
45.

Immunotoxins: magic bullets or misguided missiles?

Vitetta ES, Thorpe PE, Uhr JW.

Immunol Today. 1993 Jun;14(6):252-9. Review. Erratum in: Immunol Today. 2008 Apr;29(4):149.

PMID:
8397766
46.

Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.

Soler-Rodríguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW, Vitetta ES.

Exp Cell Res. 1993 Jun;206(2):227-34.

PMID:
8388800
47.

Immunotoxins: magic bullets or misguided missiles?

Vitetta ES, Thorpe PE, Uhr JW.

Trends Pharmacol Sci. 1993 May;14(5):148-54. Review.

PMID:
8212309
48.

Cancer dormancy: isolation and characterization of dormant lymphoma cells.

Yefenof E, Picker LJ, Scheuermann RH, Tucker TF, Vitetta ES, Uhr JW.

Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1829-33.

49.

A CD4-derived peptide carrier blocks acute HIV-1 infection in vitro and binds to gp120 in the presence of Walter-Reed stage 1-6 HIV+ sera.

Ghetie V, Wheeler T, Scott D, Uhr JW, Vitetta ES.

AIDS Res Hum Retroviruses. 1992 Nov;8(11):1945-8.

PMID:
1489581

Supplemental Content

Support Center